Bristol Myers Squibb (BMY) Divestments (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Divestments data on file, last reported at $312.0 million in Q1 2026.

• Divestments for Q1 2026 came in at $312.0 million, up 28.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 3.54% YoY), and the FY2025 annual result was $1.1 billion, down 2.55% from the prior year.
• Divestments climbed to $312.0 million in Q1 2026 per BMY's latest filing, from $279.0 million in the prior quarter.
• Over five years, Divestments peaked at $490.0 million in Q4 2022 and troughed at $192.0 million in Q2 2022.
• A 5-year average of $276.2 million and a median of $255.0 million in 2024 frame the typical range for Divestments.
• The sharpest annual moves came in 2022 and 2023: Divestments soared 175.28% in 2022, then plunged 50.82% in 2023.
• A 5-year view of Divestments shows it stood at $490.0 million in 2022, then sank by 50.82% to $241.0 million in 2023, then jumped by 38.17% to $333.0 million in 2024, then dropped by 16.22% to $279.0 million in 2025, then grew by 11.83% to $312.0 million in 2026.
• Business Quant data shows BMY's Divestments at $312.0 million in Q1 2026, $279.0 million in Q4 2025, and $279.0 million in Q3 2025.